New insights into segmental vitiligo: A clinical and immunological comparison with nonsegmental vitiligo.
Journal
Pigment cell & melanoma research
ISSN: 1755-148X
Titre abrégé: Pigment Cell Melanoma Res
Pays: England
ID NLM: 101318927
Informations de publication
Date de publication:
03 2022
03 2022
Historique:
revised:
07
10
2021
received:
11
05
2021
accepted:
04
11
2021
pubmed:
16
11
2021
medline:
30
4
2022
entrez:
15
11
2021
Statut:
ppublish
Résumé
The overlaps between segmental vitiligo (SV) and nonsegmental vitiligo (NSV) suggest the underlying features of SV, which may be helpful for treating SV. In this study, 379 vitiligo patients were recruited and divided into SV (33.2%), mild-to-moderate NSV (M-NSV, affected body affected area [BSA] ≤10%, 34.0%), and severe NSV (S-NSV, affected BSA >10%, 32.7%) groups. Demographics and clinical data were collected through in-person interviews. The disease activity, progression, and prognosis were assessed through 6 months' follow-up. Serum cytokines profile and tissue-infiltrating immune cells were measured by ELISA assay and immunofluorescence, respectively. The SV exhibited lower rates of autoimmune comorbidities and recurrence than the S-NSV, but performed similar to the M-NSV. Moreover, the disease activity, progression, serum cytokines profile, and tissue-infiltrating Th/c1 cells in the active SV and M-NSV were comparable, but differed significantly from those of the active S-NSV. The clinical and immunological similarities between SV and M-NSV presented a deeper autoimmune understanding of SV. Additionally, a classification of active vitiligo according to disease extent may be more clinically meaningful than subtypes for guiding immunomodulatory treatment.
Substances chimiques
Cytokines
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
220-228Informations de copyright
© 2021 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Références
Abdallah, M., El-Mofty, M., Anbar, T., Rasheed, H., Esmat, S., Al-Tawdy, A., Fawzy, M. M., Abdel-Halim, D., Hegazy, R., Gawdat, H., Bassiouny, D., Ibrahim, M. A., Sany, I., El-Bassiouny, M., Khalil, M., Abdel-Aziz, A., El Maadawi, Z. M., Mostafa, W. Z., & Egyptian Vitiligo Group. (2018). CXCL-10 and Interleukin-6 are reliable serum markers for vitiligo activity: A multicenter cross-sectional study. Pigment Cell & Melanoma Research, 31(2), 330-336. https://doi.org/10.1111/pcmr.12667
Agarwal, P., Rashighi, M., Essien, K. I., Richmond, J. M., Randall, L., Pazoki-Toroudi, H., Hunter, C. A., & Harris, J. E. (2015). Simvastatin prevents and reverses depigmentation in a mouse model of vitiligo. The Journal of Investigative Dermatology, 135(4), 1080-1088. https://doi.org/10.1038/jid.2014.529
Alghamdi, K. M., Kumar, A., Taïeb, A., & Ezzedine, K. (2012). Assessment methods for the evaluation of vitiligo. Journal of the European Academy of Dermatology and Venereology: JEADV, 26(12), 1463-1471. https://doi.org/10.1111/j.1468-3083.2012.04505.x
Anbar, T. S., Westerhof, W., Abdel-Rahman, A. T., & El-Khayyat, M. A. (2006). Evaluation of the effects of NB-UVB in both segmental and non-segmental vitiligo affecting different body sites. Photodermatology, Photoimmunology & Photomedicine, 22(3), 157-163. https://doi.org/10.1111/j.1600-0781.2006.00222.x
Attili, V. R., & Attili, S. K. (2013). Segmental and generalized vitiligo: Both forms demonstrate inflammatory histopathological features and clinical mosaicism. Indian Journal of Dermatology, 58(6), 433-438. https://doi.org/10.4103/0019-5154.119949
Bae, J. M., Yoo, H. J., Kim, H., Lee, J. H., & Kim, G. M. (2015). Combination therapy with 308-nm excimer laser, topical tacrolimus, and short-term systemic corticosteroids for segmental vitiligo: A retrospective study of 159 patients. Journal of the American Academy of Dermatology, 73(1), 76-82. https://doi.org/10.1016/j.jaad.2015.04.008
Craiglow, B. G., & King, B. A. (2015). Tofacitinib citrate for the treatment of vitiligo: A pathogenesis-directed therapy. JAMA Dermatology, 151(10), 1110-1112. https://doi.org/10.1001/jamadermatol.2015.1520
Ezzedine, K., Diallo, A., Léauté-Labrèze, C., Mossalayi, D., Gauthier, Y., Bouchtnei, S., Cario-André, M., Seneschal, J., Boralevi, F., Jouary, T., & Taieb, A. (2011). Multivariate analysis of factors associated with early-onset segmental and nonsegmental vitiligo: A prospective observational study of 213 patients. The British Journal of Dermatology, 165(1), 44-49. https://doi.org/10.1111/j.1365-2133.2011.10311.x
Ezzedine, K., Gauthier, Y., Leaute-Labreze, C., Marquez, S., Bouchtnei, S., Jouary, T., & Taieb, A. (2011). Segmental vitiligo associated with generalized vitiligo (mixed vitiligo): A retrospective case series of 19 patients. Journal of the American Academy of Dermatology, 65(5), 965-971.
Gholijani, N., Yazdani, M. R., & Dastgheib, L. (2020). Predominant role of innate pro-inflammatory cytokines in vitiligo disease. Archives of Dermatological Research, 312(2), 123-131. https://doi.org/10.1007/s00403-019-01996-9
Gomes, I. A., de Carvalho, F. O., de Menezes, A. F., Almeida, F. M., Shanmugam, S., de Souza Siqueira Quintans, J., Quintans-Júnior, L. J., de Moura, T. R., Oliveira, P. D., & de Souza Araújo, A. A. (2018). The role of interleukins in vitiligo: A systematic review. Journal of the European Academy of Dermatology and Venereology: JEADV, 32(12), 2097-2111.
Harris, J. E., Rashighi, M., Nguyen, N., Jabbari, A., Ulerio, G., Clynes, R., Christiano, A. M., & Mackay-Wiggan, J. (2016). Rapid skin repigmentation on oral ruxolitinib in a patient with coexistent vitiligo and alopecia areata (AA). Journal of the American Academy of Dermatology, 74(2), 370-371. https://doi.org/10.1016/j.jaad.2015.09.073
Laddha, N. C., Dwivedi, M., Mansuri, M. S., Singh, M., Gani, A. R., Yeola, A. P., Panchal, V. N., Khan, F., Dave, D. J., Patel, A., Madhavan, S. E., Gupta, R., Marfatia, Z., Marfatia, Y. S., & Begum, R. (2014). Role of oxidative stress and autoimmunity in onset and progression of vitiligo. Experimental Dermatology, 23(5), 352-353. https://doi.org/10.1111/exd.12372
Lim, H. K., Bae, M. I., Jeong, K. H., Shin, M. K., Lee, M. H. (2016). Positivity rates of antithyroid antibody, antinuclear antibody and thyroid peroxidase antibody in different types of vitiligo. Clinical and Experimental Dermatology, 41(3), 242-247. https://doi.org/10.1111/ced.12771
Mazereeuw-Hautier, J., Bezio, S., Mahe, E., Bodemer, C., Eschard, C., Viseux, V., Labreze, C., Plantin, P., Barbarot, S., Vabres, P., Martin, L., Paul, C., Lacour, J.-P., & Groupe de Recherche Clinique en Dermatologie Pédiatrique (GRCDP). (2010). Segmental and nonsegmental childhood vitiligo has distinct clinical characteristics: A prospective observational study. Journal of the American Academy of Dermatology, 62(6), 945-949. https://doi.org/10.1016/j.jaad.2009.06.081
Mulekar, S. V., Al Issa, A., Asaad, M., Ghwish, B., & Al Eisa, A. (2006). Mixed vitiligo. Journal of Cutaneous Medicine and Surgery, 10(2), 104-107. https://doi.org/10.2310/7750.2006.00018
Nicolaidou, E., Antoniou, C., Stratigos, A. J., Stefanaki, C., & Katsambas, A. D. (2007). Efficacy, predictors of response, and long-term follow-up in patients with vitiligo treated with narrowband UVB phototherapy. Journal of the American Academy of Dermatology, 56(2), 274-278. https://doi.org/10.1016/j.jaad.2006.09.004
Park, J. H., Jung, M. Y., Lee, J. H., Yang, J. M., Lee, D. Y., & Park, K. K. (2014). Clinical course of segmental vitiligo: A retrospective study of eighty-seven patients. Annals of Dermatology, 26(1), 61-65. https://doi.org/10.5021/ad.2014.26.1.61
Rashighi, M., & Harris, J. E. (2015). Interfering with the IFN-gamma/CXCL10 pathway to develop new targeted treatments for vitiligo. Annals of Translational Medicine, 3(21), 343.
Riding, R. L., & Harris, J. E. (2019). The role of memory CD8+ T cells in vitiligo. Journal of Immunology, 203(1), 11-19.
Rodrigues, M., Ezzedine, K., Hamzavi, I., Pandya, A. G., Harris, J. E., & Vitiligo Working, G. (2017). New discoveries in the pathogenesis and classification of vitiligo. Journal of the American Academy of Dermatology, 77(1), 1-13. https://doi.org/10.1016/j.jaad.2016.10.048
Sabat, R., Wolk, K., Loyal, L., Docke, W. D., & Ghoreschi, K. (2019). T cell pathology in skin inflammation. Seminars in Immunopathology, 41(3), 359-377. https://doi.org/10.1007/s00281-019-00742-7
Speeckaert, R., Mylle, S., & Van Geel, N. (2019). IL-17A is not a treatment target in progressive vitiligo. Pigment Cell and Melanoma Research, 32(6), 842-847. https://doi.org/10.1111/pcmr.12789
Taïeb, A., Picardo, M., & Members, V. E. T. F. (2007). The definition and assessment of vitiligo: A consensus report of the Vitiligo European task force. Pigment Cell Research, 20(1), 27-35. https://doi.org/10.1111/j.1600-0749.2006.00355.x
Tulic, M. K., Cavazza, E., Cheli, Y., Jacquel, A., Luci, C., Cardot-Leccia, N., Hadhiri-Bzioueche, H., Abbe, P., Gesson, M., Sormani, L., Regazzetti, C., Beranger, G. E., Lereverend, C., Pons, C., Khemis, A., Ballotti, R., Bertolotto, C., Rocchi, S., & Passeron, T. (2019). Innate lymphocyte-induced CXCR3B-mediated melanocyte apoptosis is a potential initiator of T-cell autoreactivity in vitiligo. Nature Communications, 10(1), 2178. https://doi.org/10.1038/s41467-019-09963-8
Van Geel, N., De Lille, S., Vandenhaute, S., Gauthier, Y., Mollet, I., Brochez, L., & Lambert, J. (2011). Different phenotypes of segmental vitiligo based on a clinical observational study. Journal of the European Academy of Dermatology and Venereology: JEADV, 25(6), 673-678. https://doi.org/10.1111/j.1468-3083.2010.03847.x
van Geel, N., Grine, L., De Wispelaere, P., Mertens, D., Prinsen, C. A. C., & Speeckaert, R. (2019). Clinical visible signs of disease activity in vitiligo: A systematic review and meta-analysis. Journal of the European Academy of Dermatology and Venereology: JEADV, 33(9), 1667-1675.
Van Geel, N. A. C., Mollet, I. G., De Schepper, S., Tjin, E. P. M., Vermaelen, K., Clark, R. A., Kupper, T. S., Luiten, R. M., & Lambert, J. O. (2010). First histopathological and immunophenotypic analysis of early dynamic events in a patient with segmental vitiligo associated with halo nevi. Pigment Cell and Melanoma Research, 23(3), 375-384. https://doi.org/10.1111/j.1755-148X.2010.00703.x
Van Geel, N., & Speeckaert, R. (2017). Segmental Vitiligo. Dermatologic Clinics, 35(2), 145-150. https://doi.org/10.1016/j.det.2016.11.005
Wang, X. X., Wang, Q. Q., Wu, J. Q., Jiang, M., Chen, L., Zhang, C. F., & Xiang, L. H. (2016). Increased expression of CXCR3 and its ligands in patients with vitiligo and CXCL10 as a potential clinical marker for vitiligo. The British Journal of Dermatology, 174(6), 1318-1326.
Wang, Y., Li, S., & Li, C. (2019). Perspectives of New Advances in the Pathogenesis of Vitiligo: From Oxidative Stress to Autoimmunity. Medical Science Monitor: International Medical Journal of Experimental and Clinical Research, 25, 1017-1023.
Yang, K., Xiong, X., Pallavi, G., Ling, Y., Ding, F., Duan, W., Sun, W., Ding, G., Gong, Q., Zhu, W., & Lu, Y. (2018). The early repigmentation pattern of vitiligo is related to the source of melanocytes and by the choice of therapy: A retrospective cohort study. International Journal of Dermatology, 57(3), 324-331. https://doi.org/10.1111/ijd.13878
Yang, X., Yan, L., Ha, D., Qu, L., Liu, L., & Tao, Y. (2019). Changes in sICAM-1 and GM-CSF levels in skin tissue fluid and expression of IL-6, IL-17 and TNF-alpha in blood of patients with vitiligo. Experimental and Therapeutic Medicine, 17(1), 408-412.
Zhang, L. I., Chen, S., Kang, Y., Wang, X., Yan, F., Jiang, M., Wang, Q., Liu, Z., Zhang, C., & Xiang, L. (2020). Association of clinical markers with disease progression in patients with vitiligo from China. JAMA Dermatology, 156(3), 288-295. https://doi.org/10.1001/jamadermatol.2019.4483
Zhang, L., Kang, Y., Chen, S., Wang, L., Jiang, M., & Xiang, L. (2019). Circulating CCL20: A potential biomarker for active vitiligo together with the number of Th1/17 cells. Journal of Dermatological Science, 93(2), 92-100. https://doi.org/10.1016/j.jdermsci.2018.12.005